ImmuCell Corporation Revenue from Contract with Customer, Including Assessed Tax
ImmuCell Corporation (ICCC) reported Revenue from Contract with Customer, Including Assessed Tax of $6.44 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2025-08-14
- ImmuCell Corporation revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $6.44M, a 17.76% increase year-over-year.
- ImmuCell Corporation revenue from contract with customer, including assessed tax for the quarter ending 2025-03-31 was $8.07M, a 11.16% increase year-over-year.
- ImmuCell Corporation revenue from contract with customer, including assessed tax for the quarter ending 2024-12-31 was $7.75M, a 52.10% increase year-over-year.
- ImmuCell Corporation revenue from contract with customer, including assessed tax for the quarter ending 2024-09-30 was $6.01M, a 11.40% increase year-over-year.
- ImmuCell Corporation revenue from contract with customer, including assessed tax for fiscal 2024 was $26.49M, a 51.64% increase from fiscal 2023.
- ImmuCell Corporation revenue from contract with customer, including assessed tax for fiscal 2023 was $17.47M.
- ImmuCell Corporation revenue from contract with customer, including assessed tax for fiscal 2018 was $10.99M, a 5.32% increase from fiscal 2017.
- ImmuCell Corporation revenue from contract with customer, including assessed tax for fiscal 2017 was $10.43M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-06-30 | $6.44M 10-Q · filed 2025-08-14 | $14.51M 10-Q · filed 2025-08-14 | $22.26M derived: sum of 3 quarters · filed 2025-08-14 | $28.27M derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $8.07M 10-Q · filed 2025-05-14 | $15.82M derived: sum of 2 quarters · filed 2025-05-14 | $21.83M derived: sum of 3 quarters · filed 2025-05-14 | $27.30M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $13.76M derived: sum of 2 quarters · filed 2025-03-28 | $19.24M derived: sum of 3 quarters · filed 2025-08-14 | $26.49M 10-K · filed 2025-03-28 |
| 2024-09-30 | $6.01M 10-Q · filed 2024-11-13 | $11.48M derived: sum of 2 quarters · filed 2025-08-14 | $18.74M 10-Q · filed 2024-11-13 | $23.84M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-06-30 | $5.47M 10-Q · filed 2025-08-14 | $12.73M 10-Q · filed 2025-08-14 | $17.83M derived: sum of 3 quarters · filed 2025-08-14 | $23.22M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $7.26M 10-Q · filed 2025-05-14 | $12.35M derived: sum of 2 quarters · filed 2025-05-14 | $17.75M derived: sum of 3 quarters · filed 2025-05-14 | $21.28M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $10.49M derived: sum of 2 quarters · filed 2025-03-28 | $14.03M derived: sum of 3 quarters · filed 2025-03-28 | $17.47M 10-K · filed 2025-03-28 |
| 2023-09-30 | $5.40M 10-Q · filed 2024-11-13 | $8.93M derived: sum of 2 quarters · filed 2024-11-13 | $12.38M 10-Q · filed 2024-11-13 | $16.29M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $3.53M 10-Q · filed 2024-08-13 | $6.98M 10-Q · filed 2024-08-13 | $10.89M derived: sum of 3 quarters · filed 2024-11-13 | $15.69M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-03-31 | $3.45M 10-Q · filed 2024-05-14 | $7.36M derived: sum of 2 quarters · filed 2024-11-13 | $12.15M derived: sum of 3 quarters · filed 2024-11-13 | $16.01M derived: sum of 4 quarters · filed 2024-11-13 |
| 2022-12-31 | $3.91M derived: 10-Q 12 month − 10-Q 9 month · filed 2024-11-13 | $8.71M derived: sum of 2 quarters · filed 2024-11-13 | $12.57M derived: sum of 3 quarters · filed 2024-11-13 | $18.57M 10-Q · filed 2024-11-13 |
| 2022-09-30 | $4.80M 10-Q · filed 2023-11-13 | $8.66M derived: sum of 2 quarters · filed 2023-11-13 | $14.66M 10-Q · filed 2023-11-13 | $20.10M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $3.86M 10-Q · filed 2023-08-10 | $9.86M 10-Q · filed 2023-08-10 | $15.30M derived: sum of 3 quarters · filed 2023-11-13 | $20.46M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-03-31 | $6.00M 10-Q · filed 2023-05-11 | $11.44M derived: sum of 2 quarters · filed 2023-11-13 | $16.59M derived: sum of 3 quarters · filed 2023-11-13 | $21.14M derived: sum of 4 quarters · filed 2023-11-13 |
| 2021-12-31 | $5.44M derived: 10-Q 12 month − 10-Q 9 month · filed 2023-11-13 | $10.59M derived: sum of 2 quarters · filed 2023-11-13 | $15.14M derived: sum of 3 quarters · filed 2023-11-13 | $19.24M 10-Q · filed 2023-11-13 |
| 2021-09-30 | $5.15M 10-Q · filed 2022-11-21 | $9.69M derived: sum of 2 quarters · filed 2022-11-21 | $13.80M 10-Q · filed 2022-11-21 | $17.54M derived: sum of 4 quarters · filed 2022-11-21 |
| 2021-06-30 | $4.54M 10-Q/A · filed 2022-11-21 | $8.65M 10-Q/A · filed 2022-11-21 | $12.39M derived: sum of 3 quarters · filed 2022-11-21 | $16.11M derived: sum of 4 quarters · filed 2022-11-21 |
| 2021-03-31 | $4.11M 10-Q/A · filed 2022-11-21 | $7.85M derived: sum of 2 quarters · filed 2022-11-21 | $11.57M derived: sum of 3 quarters · filed 2022-11-21 | $14.54M derived: sum of 4 quarters · filed 2022-11-21 |
| 2020-12-31 | $3.74M derived: 10-Q/A 12 month − 10-Q 9 month · filed 2022-11-21 | $7.47M derived: sum of 2 quarters · filed 2022-11-21 | $10.43M derived: sum of 3 quarters · filed 2022-11-21 | $15.34M 10-Q/A · filed 2022-11-21 |
| 2020-09-30 | $3.72M 10-Q · filed 2021-11-15 | $6.69M derived: sum of 2 quarters · filed 2021-11-15 | $11.60M 10-Q · filed 2021-11-15 | $15.23M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $2.97M 10-Q · filed 2021-08-12 | $7.88M 10-Q · filed 2021-08-12 | $11.51M derived: sum of 3 quarters · filed 2021-08-12 | $14.48M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $4.91M 10-Q · filed 2021-05-13 | $8.54M derived: sum of 2 quarters · filed 2021-05-13 | $11.51M derived: sum of 3 quarters · filed 2021-05-13 | $14.22M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $3.63M derived: 10-Q 12 month − 10-Q 9 month · filed 2021-05-13 | $6.60M derived: sum of 2 quarters · filed 2021-05-13 | $9.31M derived: sum of 3 quarters · filed 2021-05-13 | $13.72M 10-Q · filed 2021-05-13 |
| 2019-09-30 | $2.97M 10-Q · filed 2020-11-12 | $5.68M derived: sum of 2 quarters · filed 2020-11-12 | $10.09M 10-Q · filed 2020-11-12 | $13.03M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $2.71M 10-Q · filed 2020-08-12 | $7.12M 10-Q · filed 2020-08-12 | $10.06M derived: sum of 3 quarters · filed 2020-08-12 | $12.21M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | $4.41M 10-Q · filed 2020-05-13 | $7.35M derived: sum of 2 quarters · filed 2020-05-13 | $9.50M derived: sum of 3 quarters · filed 2020-05-13 | $12.52M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $2.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $5.09M derived: sum of 2 quarters · filed 2020-03-27 | $8.11M derived: sum of 3 quarters · filed 2020-03-27 | $10.99M 10-K · filed 2020-03-27 |
| 2018-09-30 | $2.15M 10-Q · filed 2019-11-12 | $5.17M derived: sum of 2 quarters · filed 2019-11-12 | $8.05M 10-Q · filed 2019-11-12 | $11.18M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $3.01M 10-Q · filed 2019-08-12 | $5.90M 10-Q · filed 2019-08-12 | $9.03M derived: sum of 3 quarters · filed 2019-08-12 | $11.03M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $2.88M 10-Q · filed 2019-05-13 | $6.01M derived: sum of 2 quarters · filed 2019-05-13 | $8.02M derived: sum of 3 quarters · filed 2019-05-13 | $9.77M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $5.14M derived: sum of 2 quarters · filed 2019-03-22 | $6.89M derived: sum of 3 quarters · filed 2019-03-22 | $10.43M 10-K · filed 2019-03-22 |
| 2017-09-30 | $2.00M 10-Q · filed 2018-11-13 | $3.75M derived: sum of 2 quarters · filed 2018-11-13 | $7.30M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $1.75M 10-Q · filed 2018-08-13 | $5.29M 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |